• LLY
• NVO

Novo Nordisk defends next-gen obesity drug CagriSema, details new trial

Novo Nordisk remains optimistic about CagriSema, a new obesity drug, despite disappointing trial results. Plans for further trials and regulatory submission are in place to enhance its market potential.

• AAPL
• ASML
• DBKGn
• MSFT
• NVO
• STOXX
• TSLA

Take Five: Fed, ECB - and more from Trump

• ASML
• CFR
• DBKGn
• EUR/USD
• LXSG
• NVO
• US500

Analysis-European earnings may keep the mood sweet as tariff fears grow

European companies are expected to report profit growth despite economic uncertainty, with high investor interest. US tariffs and global factors influence market performance.

• CARLb
• NVO
• PANDY

Denmark's prime minister summons business leaders following Trump's Greenland threat

Prime Minister Mette Frederiksen of Denmark convened business leaders after Trump's controversial remarks about Greenland's control, emphasizing dialogue and cooperation amid rising geopolitical tensions.

• BIIB
• JNJ
• LLY
• NBI
• NVO
• PFE
• US500

Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return

The biopharmaceutical industry seeks to rebound in 2025, navigating uncertainty from regulatory changes and potential impacts from President Trump's administration on drug pricing and vaccine policies.

• LLY
• NVO

Retail investors buy Novo dip after disappointing weight-loss drug data

Retail investor interest in Novo Nordisk surged after underwhelming obesity drug data, leading to a significant dip in share price while comparisons with Eli Lilly highlighted rising competition in weight-loss treatments.

• NOVOb
• NVO

Novo Nordisk shares rally despite setback in obesity drug trial results

Novo Nordisk's shares rose over 5% after a major market drop due to disappointing results from their obesity drug CagriSema's phase 3 trial.

• NOVOb
• NVO

Novo Nordisk shares rebound despite disappointing CagriSema trial results

Novo Nordisk's CagriSema trial showed disappointing weight loss results, leaving room for Lilly to maintain dominance in the obesity treatment market with its competing therapies.

• AV
• DLGD
• NVO
• STOXX
• VOWG_p

STOXX 600 inches lower at start of Christmas week; Novo Nordisk surges

European markets see mixed trends as Novo Nordisk's share surge offsets losses in travel and leisure sectors amid economic concerns and ECB predictions influencing investor sentiment.

• LLY
• NVO

Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea

The FDA approved Eli Lilly's Zepbound for treating obstructive sleep apnea in obese adults, marking a significant advancement in addressing this widespread disorder and expanding market potential.